tocilizumab living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID-19 severe or critically

	COVID-19 severe or critically
tocilizumab	Veiga MARIPOSA Talaschian COVACTA ... CORIMUNO-TOCI-ICU ... CORIMUNO-TOCI-1 ... REMAP-CAP ... Rosas ...

5444	TOCI-RAF Study Group (Campochiaro), 2020	1	13	0		not a RCT	risk of bias not avaialble
5489	Rojas-Marte, 2020	1	13	4		not a RCT	high risk of bias
5522	Somers, 2020	1	13	4		not a RCT	high risk of bias
5528	Mathilde, 2020	1	13	4		not a RCT	high risk of bias
5529	Andrew, 2020	1	13	0		not a RCT	risk of bias not avaialble
5616	Biran, 2020	1	13	3		not a RCT	high risk of bias
5628	Rossotti, 2020	1	13	4		not a RCT	high risk of bias
5632	Holt, 2020	2	13	0	excluded	not a RCT	risk of bias not avaialble
5672	Klopfenstein, 2020	2	13	4	excluded	not a RCT	high risk of bias
5941	Zeng, 2020	0	30	0	selection pending
5965	Pereira, 2020	0	99	0	selection pending
6281	Roumier, 2020	0	10	0	selection pending
6282	Menzella, 2020	0	13	0	selection pending
6335	Ruiz-Antoran, 2020	0	13	0	selection pending
6414	Mikulska, 2020	0	13	0	selection pending
6418	Guaraldi, 2020	0	13	0	selection pending
6420	Potere, 2020	0	20	0	selection pending
6425	Roumier, 2020	0	13	0	selection pending
6429	Kewan, 2020	0	13	0	selection pending
6431	Moreno-Pérez, 2020	0	13	0	selection pending
6433	Canziani, 2020	0	20	0	selection pending
6435	Gokhale, 2020	0	13	0	selection pending
7007	Rashad, 2021	1	1	3			high risk of bias
8156	Hamed, 2021	1	1	3			high risk of bias
8509	Karampitsakos, 2021	0	31	0	selection pending
8960	NCT04377750 (HMO-0224-20), 0	1	1	3			high risk of bias
9133	Karakike (ESCAPE), 2021	0	31	0	selection pending
9225	Belhassen-Garc??a, 2021	0	11	0	selection pending
9243	Sarhan, 2022	0	1	0	selection pending